Gilead Sciences Announces Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
UPDATE: BMO Capital Maintains Gilead Sciences (GILD) at Market Perform (Correction)
November 2, 2016 6:56 AM EDT(Updated - November 2, 2016 7:17 AM EDT)
(Gilead was not upgraded to Outperform, remains Market Perform at BMO.)
BMO Capital maintained its Market Perform rating on Gilead Sciences (NASDAQ: GILD) with a price target of $84 (prior $98). Comments follow Q3 results.... More
Gilead Sciences (GILD) Misses Q3 EPS by 11c; Reiterates Outlook
November 1, 2016 4:03 PM EDTGilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.75, $0.11 worse than the analyst estimate of $2.86. Revenue for the quarter came in at $7.4 billion versus the consensus estimate of $7.45 billion.Gilead Sciences reaffirmed FY2016... More
